Uniplan Investment Counsel Inc. Makes New $475,000 Investment in Dynavax Technologies Corporation $DVAX

Key Points

• Uniplan Investment Counsel Inc. has acquired 36,585 shares of Dynavax Technologies, valued at approximately $475,000, as part of their new position in the company.
• Institutional investors own 96.96% of Dynavax Technologies' stock, with significant growth in holdings reported by firms like Invesco Ltd. and Walleye Capital LLC in the first quarter.
• Dynavax Technologies reported a quarterly earnings per share of $0.14, surpassing the consensus estimate of $0.12, alongside revenue of $95.44 million, exceeding analyst expectations.

Uniplan Investment Counsel Inc. purchased a new stake in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 36,585 shares of the biopharmaceutical company's stock, valued at approximately $475,000.

Other hedge funds have also recently bought and sold shares of the company. Invesco Ltd. raised its stake in shares of Dynavax Technologies by 33.8% during the first quarter. Invesco Ltd. now owns 2,207,631 shares of the biopharmaceutical company's stock valued at $28,633,000 after purchasing an additional 558,046 shares during the period. D. E. Shaw & Co. Inc. raised its stake in shares of Dynavax Technologies by 34.0% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,918,340 shares of the biopharmaceutical company's stock valued at $24,497,000 after purchasing an additional 486,981 shares during the period. Cubist Systematic Strategies LLC raised its stake in shares of Dynavax Technologies by 237.4% during the first quarter. Cubist Systematic Strategies LLC now owns 656,541 shares of the biopharmaceutical company's stock valued at $8,515,000 after purchasing an additional 461,980 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Dynavax Technologies during the first quarter valued at approximately $4,370,000. Finally, Walleye Capital LLC raised its stake in shares of Dynavax Technologies by 50,734.1% during the first quarter. Walleye Capital LLC now owns 266,879 shares of the biopharmaceutical company's stock valued at $3,461,000 after purchasing an additional 266,354 shares during the period. Hedge funds and other institutional investors own 96.96% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on DVAX. Wall Street Zen upgraded shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. JMP Securities reiterated a "market outperform" rating and set a $32.00 price objective on shares of Dynavax Technologies in a research note on Friday, August 22nd. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $24.33.

Dynavax Technologies Stock Down 3.4%

Shares of NASDAQ:DVAX traded down $0.33 during midday trading on Friday, reaching $9.41. The company had a trading volume of 1,650,058 shares, compared to its average volume of 1,815,138. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.65 and a quick ratio of 6.01. The stock's fifty day moving average price is $10.59 and its 200-day moving average price is $11.08. The stock has a market capitalization of $1.10 billion, a P/E ratio of -20.46 and a beta of 1.24. Dynavax Technologies Corporation has a one year low of $9.22 and a one year high of $14.63.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.02. The business had revenue of $95.44 million during the quarter, compared to analyst estimates of $87.55 million. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. Equities research analysts expect that Dynavax Technologies Corporation will post 0.32 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Scott Dunseth Myers purchased 3,800 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was acquired at an average price of $10.82 per share, for a total transaction of $41,116.00. Following the completion of the purchase, the director owned 35,004 shares in the company, valued at approximately $378,743.28. This represents a 12.18% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 2.98% of the company's stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.